8-K: United-Guardian Reports Lower First Quarter Results Due to Cosmetic Ingredient Sales Decline

United-Guardian's first quarter sales and net income decreased in 2025 compared to 2024, primarily due to a significant drop in cosmetic ingredient sales.

Summary

• United-Guardian announced its financial results for the first quarter of 2025.
• First quarter sales decreased to $2,481,127 in 2025 from $3,254,944 in 2024.
• Net income also decreased from $925,442 ($0.20 per share) to $560,895 ($0.12 per share).
• The decrease in sales and earnings was primarily due to a decline in the cosmetic ingredient business.
• Medical lubricant and pharmaceutical sales increased by 43% and 23%, respectively.
• Cosmetic ingredient sales decreased by 63% due to reduced orders from Ashland Specialty Ingredients (ASI).
• ASI attributed the decrease to excess inventory in China and order timing.
• Tariff announcements by the U.S. federal government remain a concern for the business.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the decrease in sales and net income, particularly the significant drop in cosmetic ingredient sales. However, the increases in medical lubricant and pharmaceutical sales provide some offset.

Positives

• Medical lubricant sales increased by 43% in the first quarter of 2025 compared to the same period in 2024.
• Pharmaceutical sales increased by 23% in the first quarter of 2025 compared to the same period in 2024.
• ASI has confirmed that currently there has been no significant loss of business or customers.

Negatives

• First quarter sales decreased from $3,254,944 in 2024 to $2,481,127 in 2025.
• Net income decreased from $925,442 ($0.20 per share) to $560,895 ($0.12 per share).
• Cosmetic ingredients sales decreased by 63% in the first quarter of 2025.

Risks

• Tariff announcements by the executive branch of the U.S. federal government on imports from various countries remain a concern for the business.
• The company is uncertain about the potential impact of tariffs on its operations or financial condition.

Future Outlook

The company expresses concern regarding the potential impact of U.S. federal government tariff announcements on imports from various countries, noting uncertainty about the effects on operations and financial condition.

Management Comments

• Donna Vigilante, President of United-Guardian, stated, 'We are experiencing a slow start to 2025 compared to the beginning of 2024.'
• Donna Vigilante stated that the decrease in sales and earnings was primarily due to a decrease in the cosmetic ingredient business.

Industry Context

The decrease in cosmetic ingredient sales highlights the potential volatility in the specialty chemicals market, where demand can be influenced by factors such as inventory levels at major customers like Ashland Specialty Ingredients (ASI). The company's reliance on a few key customers makes it vulnerable to fluctuations in their order patterns. The concern over tariffs reflects broader anxieties within the manufacturing sector regarding international trade policies.

Comparison to Industry Standards

• United-Guardian's performance can be compared to companies in the specialty chemicals and personal care ingredients sectors.
• Companies like Ashland, Croda International, and Evonik Industries are key players in this space.
• A 63% decrease in cosmetic ingredient sales is significant and would likely be viewed negatively compared to the growth rates of competitors in that segment.
• The 43% and 23% increases in medical lubricant and pharmaceutical sales, respectively, are positive and could be compared to the growth rates of companies focused on those specific markets.

Stakeholder Impact

• Shareholders may be concerned about the decrease in sales and net income.
• Employees in the cosmetic ingredients division may face uncertainty due to the sales decline.
• Customers may be affected by potential changes in product availability or pricing due to tariff concerns.

Key Dates

Keywords

financial results, first quarter, United-Guardian, cosmetic ingredients, medical lubricants, pharmaceuticals, sales decrease, net income, tariffs